New hope for tough lymphoma: TR115 faces off against standard care
Disease control
Not yet recruiting
This study tests a new drug called TR115 in about 180 adults with a rare blood cancer (T/NK-cell lymphoma) that has come back or not responded to prior treatments. Participants will receive either TR115 or one of several standard drugs. The main goal is to see if TR115 can slow c…
Phase: PHASE3 • Sponsor: Tarapeutics Science Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC